2Laboratory of Mammalian Cell Bioengineering, Research Center of Biotechnology, Skryabin Institute of Bioengineering, Russian Academy of Sciences, 119071 Moscow, Russia
3Immunology and Biomedicine Program, Center for Genetics and Life Sciences, Sirius University of Science and Technology, 354340 Sochi, Krasnodar Krai, Russia
4Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
5Laboratory of Immunobiochemistry, Research Center of Biotechnology, Bach Institute of Biochemistry, Russian Academy of Sciences, 119071 Moscow, Russia
* To whom correspondence should be addressed.
Received: January 28, 2026; Revised: March 2, 2026; Accepted: March 6, 2026
Escherichia coli is one of the most common producers of recombinant proteins, including therapeutic antibody fragments. However, the outer membrane of E. coli contains high levels of lipopolysaccharide (LPS, also known as endotoxin), which can activate innate immune receptors, trigger immune responses, and induce systemic inflammation that may progress to septic shock. Ensuring extremely low endotoxin levels in preparations intended for in vivo applications is critically important. In this study, we investigated the endotoxin content in preparations of the bispecific mini-antibody MYSTI-2 produced in two E. coli strains: the Rosetta strain, which synthesizes conventional LPS, and the ClearColi strain, which synthesizes potentially non-toxic form of LPS. Our results demonstrate that near-complete removal of LPS can be achieved only through the use of a non-ionic detergent during purification, regardless of the bacterial strain used for protein production.
KEY WORDS: recombinant proteins, endotoxin, bispecific antibodiesDOI: 10.1134/S0006297926600225
Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.